Anwendungen

ApnoeCPAP

"" ""

ApnoeCPAP

Apnoe und Atemunregelmäßigkeiten kommen bei fast allen Früh- und Neugeborenen vor. Je frühzeitiger das Kind geboren wurde, desto ausgeprägter tritt die Apnoe auf. Hierbei kommt es zu einer Unterbrechung der Atemmechanik und der Atemkontrolle. Das gravierendste Merkmal der Apnoe ist der nicht kontinuierliche Luftstrom in den Atemwegen des Patienten.

Apnoe ist für den Patienten aufgrund der Begleitsymptome wie Bradykardie <80 BPM (verringerte Herzfrequenz) und Hypoxie <80 % (verringerte Sauerstoffsättigung) klinisch relevant. Ziel der Prophylaxe und Behandlung von Apnoe ist es, negative Auswirkungen zu vermeiden oder zu minimieren (Pantalitschka T, Sievers J, Urschitz MS, Herberts T, Reher C, Poets CF. Randomised crossover trial of four nasal respiratory support systems for apnoea of prematurity in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2009;94(4):F245-F248. doi:10.1136/adc.2008.1489811​, Therapie idiopatischer Apnoen, Bradykardien und Hypoxämien2​).

  • Zusätzliche Atemhübe stimulieren die Atmung

  • Die Atemwege werden stabilisiert, wodurch die Atmung erleichtert wird

  • Die Eigenatmung des Patienten wird erkannt und das Gerät wechselt in den CPAP-Modus

  • Verfügbar bei den Geräten medinCNO, medinCNOmini, medin-NC3

Bedeutung von nCPAP für die Apnoe-Therapie

Die Wirksamkeit der nasalen CPAP ist in diesem Kontext durch Studien belegt und Bestandteil der anwendbaren Richtlinien für die Behandlung der Apnoe und ihrer Begleitsymptome (Pantalitschka T, Sievers J, Urschitz MS, Herberts T, Reher C, Poets CF. Randomised crossover trial of four nasal respiratory support systems for apnoea of prematurity in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2009;94(4):F245-F248. doi:10.1136/adc.2008.1489811​, Therapie idiopatischer Apnoen, Bradykardien und Hypoxämien2​, De Paoli AG, Davis PG, Faber B, Morley CJ. Devices and pressure sources for administration of nasal continuous positive airway pressure (nCPAP) in preterm neonates. Cochrane Database Syst Rev. 2008;2008(1):CD002977. Published 2008 Jan 23. doi:10.1002/14651858.CD002977.pub23).

Die Wirkungsmechanismen sind:

  • Offenhalten der Atemwege durch positiven Druck
  • Erhöhung der funktionellen Residualkapazität (FRC)
  • Erhöhung des Atemantriebs durch verbesserte Oxygenierung
  • Verringerung der Atembemühungen

ApnoeCPAP-Behandlung

Der medin ApnoeCPAP-Modus mit Apnoe-Behandlung kann von der Prophylaxe bis zur Behandlung einer bestehenden Apnoe eingesetzt werden.

Basierend auf dem nCPAP-Modus erkennt die einzigartige MediTRIG-Technologie zentrale und obstruktive Apnoen und reagiert mit automatischen zusätzlichen Atemhüben durch das CPAP-Gerät darauf. Die Höhe des Spitzendrucks der Atemhübe wird mit einem zweiten elektronischen Flowmeter eingestellt und zum Basisflow addiert. Sowohl die Parameter der ApnoeCPAP-Funktion als auch die des MediTRIG können individuell an den Patienten angepasst werden.

""

Folgende Parameter können eingestellt werden

  • Triggersensitivität: +/- mbar. Oberer und unterer Triggerschwellenwert als Druckdifferenz in Bezug auf den PEEP
  • Apnoezeit: Von 2 s bis 20 s; Dauer der Atempause, bis das Gerät reagiert
  • Inspirationszeit: Von 0,2 s bis 2 s. Dauer des Atemhubs
  • Push-Flow: Zusätzlich einstellbarer Atemgasflow, mit dem der Spitzendruck erzeugt werden kann
  • Backup-Frequenz: Anzahl der automatischen Atemhübe pro Minute, die dem Patienten nach Ende der Apnoezeit verabreicht werden

1 Apnoe
2 Automatischer Atemhub

Randomised crossover trial of four nasal respiratory support systems for apnoea of prematurity in very low birthweight infants.

Pantalitschka T, Sievers J, Urschitz MS, Herberts T, Reher C, Poets CF. Randomised crossover trial of four nasal respiratory support systems for apnoea of prematurity in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2009;94(4):F245-F248. doi:10.1136/adc.2008.148981



BACKGROUND

Apnoea of prematurity (AOP) is a common problem in preterm infants which can be treated with various modes of nasal continuous positive airway pressure (NCPAP) or nasal intermittent positive pressure ventilation (NIPPV). It is not known which mode of NCPAP or NIPPV is most effective for AOP.

OBJECTIVE

To assess the effect of four NCPAP/NIPPV systems on the rate of bradycardias and desaturation events in very low birthweight infants.

METHODS

Sixteen infants (mean gestational age at time of study 31 weeks, 10 males) with AOP were enrolled in a randomised controlled trial with a crossover design. The infants were allocated to receive nasal pressure support using four different modes for 6 h each: NIPPV via a conventional ventilator, NIPPV and NCPAP via a variable flow device, and NCPAP delivered via a constant flow underwater bubble system. The primary outcome was the cumulative event rate of bradycardias (< or =80 beats per minute) and desaturation events (< or =80% arterial oxygen saturation), which was obtained from cardio-respiratory recordings.

RESULTS

The median event rate was 6.7 per hour with the conventional ventilator in NIPPV mode, and 2.8 and 4.4 per hour with the variable flow device in NCPAP and NIPPV mode, respectively (p value<0.03 for both compared to NIPPV/conventional ventilator). There was no significant difference between the NIPPV/conventional ventilator and the underwater bubble system.

CONCLUSION

A variable flow NCPAP device may be more effective in treating AOP in preterm infants than a conventional ventilator in NIPPV mode. It remains unclear whether synchronised NIPPV would be even more effective.

Therapie idiopatischer Apnoen, Bradykardien und Hypoxämien

Christian F. Poets, Abt. für Neonatologie, Universitätsklinikum Tübingen; GNPI; Bettina Bohnhorst, Klinik für Pädiatr. Pneumologie, Allergologie u. Neonatologie, Medizinische Hochschule Hannover; GNPI; Gunter Kerst, Klinik für Kinderkardiologie, Universitätsklinikum RWTH Aachen; DGKJ; AWMF-Leitlinien-Register Nr. 024/013 Entwicklungsstufe S2k; 1997

Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates.

De Paoli AG, Davis PG, Faber B, Morley CJ. Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates. Cochrane Database Syst Rev. 2008;2008(1):CD002977. Published 2008 Jan 23. doi:10.1002/14651858.CD002977.pub2



BACKGROUND

Nasal continuous positive airway pressure (NCPAP) is used to support preterm infants recently extubated, those experiencing significant apnoea of prematurity and those with respiratory distress soon after birth as an alternative to intubation and ventilation. This review focuses exclusively on identifying the most effective pressure source and interface for NCPAP delivery in preterm infants.

OBJECTIVES

To determine which technique of pressure generation and which type of nasal interface for NCPAP delivery most effectively reduces the need for additional respiratory support in preterm infants extubated to NCPAP following intermittent positive pressure ventilation (IPPV) for respiratory distress syndrome (RDS) or in those treated with NCPAP soon after birth.

SEARCH STRATEGY

The strategy included searches of MEDLINE (1966 - 2006), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 4, 2006) CINAHL, abstracts from conference proceedings, cross-referencing of previous reviews and the use of expert informants.

SELECTION CRITERIA

Randomised or quasi-randomised trials comparing different techniques of NCPAP pressure generation and/or nasal interfaces in preterm infants extubated to NCPAP following IPPV for RDS or treated with NCPAP soon after birth.

DATA COLLECTION AND ANALYSIS

Data was extracted and analysed by the first three authors. Dichotomous results were analysed using the relative risk (RR), risk difference (RD) and number needed to treat (NNT).

MAIN RESULTS

1. Preterm infants being extubated to NCPAP following a period of IPPV for RDS:Meta-analysis of the results from Davis 2001 and Roukema 1999a demonstrated that short binasal prongs are more effective at preventing re-intubation than single nasal or nasopharyngeal prongs [typical RR 0.59 (CI: 0.41, 0.85), typical RD -0.21 (CI: -0.35, -0.07), NNT 5 (CI: 3, 14)]. In one study comparing short binasal prong devices (Sun 1999), the re-intubation rate was significantly lower with the Infant Flow Driver than with the Medicorp prong [RR 0.33 (CI: 0.17, 0.67), RD -0.32 (CI: -0.49, -0.15), NNT 3 (CI: 2, 7)]. The other study comparing short binasal prong devices (Infant Flow Driver versus INCA prongs, Stefanescu 2003) demonstrated no significant difference in the re-intubation rate but did show a significant reduction in the total days in hospital in the Infant Flow Driver group [MD -12.60 (95% CI: -22.81, -2.39) days].2. Preterm infants primarily treated with NCPAP soon after birth:In the one trial identified, Mazzella 2001 found a significantly lower oxygen requirement and respiratory rate in those randomised to short binasal prongs when compared with CPAP delivered via nasopharyngeal prong. The requirement for intubation beyond 48 hours from randomisation was not assessed.3. Studies randomising preterm infants to different NCPAP systems using broad inclusion criteriaThe studies of Rego 2002 and Buettiker 2004 did not examine the primary outcomes of this review. Of the secondary outcomes, Rego 2002 demonstrated a significantly higher incidence of nasal hyperaemia with the use of the Argyle prong compared with Hudson prongs [RR 2.39 (95% CI: 1.27, 4.50), RD 0.28 (95% CI: 0.10, 0.46)]. One study comparing different techniques of pressure generation is awaiting further assessment as it is currently available in abstract form only.

AUTHORS' CONCLUSIONS

Short binasal prong devices are more effective than single prongs in reducing the rate of re-intubation. Although the Infant Flow Driver appears more effective than Medicorp prongs the most effective short binasal prong device remains to be determined. The improvement in respiratory parameters with short binasal prongs suggests they are more effective than nasopharyngeal CPAP in the treatment of early RDS. Further studies incorporating longer-term outcomes are required. Studies are also needed to determine the optimal pressure source for the delivery of NCPAP.